المؤلفون: D. J Ouyang (11335068), Q. T Chen (11335071), M. Anwar (10404872), N. Xie (7698083), Q. C. Ouyang (11335074), P. Z. Fan (11335077), L. Y. Qian (11335080), G. N. Chen (11335083), E. X. Zhou (11335086), L. Guo (4453888), X. W. Gu (11335089), B. N. Ding (11335092), X. H. Yang (11335095), L. P. Liu (11335098), C. Deng (6652631), Z. Xiao (3604901), J. Li (51350), Y. Q. Wang (4918831), S. Zeng (11335101), Shouman Wang (3842485), Wenjun Yi (8888957)

مصطلحات موضوعية: Pharmacology, Basic Pharmacology, Clinical Pharmacology and Therapeutics, Clinical Pharmacy and Pharmacy Practice, Pharmaceutical Sciences, Pharmacogenomics, Toxicology (incl. Clinical Toxicology), Pharmacology and Pharmaceutical Sciences not elsewhere classified, pyrotinib, lapatinib-treated, lapatinib-naive, HER2 breast cancer, metastases

Relation: https://figshare.com/articles/figure/Image1_The_Efficacy_of_Pyrotinib_as_a_Third-_or_Higher-Line_Treatment_in_HER2-Positive_Metastatic_Breast_Cancer_Patients_Exposed_to_Lapatinib_Compared_to_Lapatinib-Naive_Patients_A_Real-World_Study_pdf/16443816

الاتاحة: https://doi.org/10.3389/fphar.2021.682568.s001